Questions

1269. Deputy Michael Healy-Rae asked the Minister for Health the reason a person (details supplied) needs to apply for the treatment abroad scheme; if consideration will be given to the introduction of multi-annual or long-term approvals for patients with this rare condition; and if she will make a statement on the matter. [30880/26]

1270. Deputy George Lawlor asked the Minister for Health if she will intervene to ensure that an urgent care plan is provided for a person (details supplied) who has been assessed for urgent dental treatment which is not available through Wexford primary care centre; and if she will make a statement on the matter. [30883/26]

1271. Deputy Albert Dolan asked the Minister for Health the current status of the health and support services committed to on 10 November 2025 for the four Magdalene survivors who undertook a hunger strike; whether all of the agreed services have now been put in place; if not, the elements which remain outstanding; the reasons for any delay; and when she expects the full package of supports to be delivered. [30884/26…

1272. Deputy Albert Dolan asked the Minister for Health to provide a clear timeline for the introduction and delivery of the new health card promised to Magdalene survivors; the specific healthcare services and entitlements to be attached to the card; when survivors can expect to receive it; and the steps being taken to ensure that delays do not continue to impact access to necessary healthcare supports. [30885/26]

1273. Deputy Ruairí Ó Murchú asked the Minister for Health further to Parliamentary Question No. 129 of 21 April 2026, if she will make available the HPRA policy paper provided to her Department on the options that could be considered when it comes to cosmetic and derma fillers; and if she will make a statement on the matter. [30896/26]

1274. Deputy Roderic O'Gorman asked the Minister for Health the reason imvaggis is not covered by the free HRT scheme; if consideration can be given to its inclusion in the scheme; and if she will make a statement on the matter. [30897/26]

1275. Deputy Ivana Bacik asked the Minister for Health if she will clarify matters of interpretation regarding the Health (Assisted Human Reproduction) Act 2024 and Children and Family Relationships Act 2015 (details supplied). [30900/26]

1276. Deputy Pádraig O'Sullivan asked the Minister for Health whether her Department has identified which of the medicines currently in shortage across the European Union may pose a risk of shortage in Ireland; the measures in place to ensure continuity of supply and minimise patient impact; and if she will make a statement on the matter. [30904/26]

1277. Deputy Ruairí Ó Murchú asked the Minister for Health if there are plans to include rheumatoid arthritis on the long-term illness scheme list; and if she will make a statement on the matter. [30913/26]

1278. Deputy Cormac Devlin asked the Minister for Health if she will provide an update on the NCPE appraisal of ritlecitinib (litfulo) for severe alopecia areata, including current stage, any ongoing HSE pricing and reimbursement engagement with the applicant, expected timelines for a decision, and proposed prescribing setting if approved (details supplied); and if she will make a statement on the matter. [30914/26]

1279. Deputy Cormac Devlin asked the Minister for Health if an application has been received by the HSE for pricing and reimbursement of baricitinib for the alopecia areata indication; if not, whether the HSE or her Department has engaged with the marketing authorisation holder regarding a submission (details supplied); and if she will make a statement on the matter. [30915/26]

1280. Deputy Cormac Devlin asked the Minister for Health whether her Department, the HSE or the HPRA has engaged with the manufacturer of deuruxolitinib (leqselvi) regarding plans for EU submission and availability in Ireland; whether any named-patient or compassionate access requests have been received (details supplied); and if she will make a statement on the matter. [30916/26]

1281. Deputy Cormac Devlin asked the Minister for Health if she will outline whether JAK inhibitor treatments for severe alopecia areata, where reimbursed, will be provided via the High Tech Arrangement; the intended initiation and monitoring setting; the proposed stop rules; the estimated annual budget impact and eligible patient numbers (details supplied); and if she will make a statement on the matter. [30917/26]

1282. Deputy Cormac Devlin asked the Minister for Health the number of patients treated for alopecia areata with JAK inhibitors in public hospitals in each of the past three years, by CHO and by medicine, including any named-patient access, and associated monitoring protocols; and if she will make a statement on the matter. [30918/26]

1283. Deputy Cormac Devlin asked the Minister for Health if she will publish a national clinical pathway for alopecia areata within the HSE Model of Care for Dermatology, covering diagnostic criteria, severity thresholds (for example, SALT scoring), first- and second-line options (including intralesional steroids, topical immunotherapy and JAK inhibitors), vaccination guidance, monitoring schedules and stop rules; an…

1284. Deputy Cormac Devlin asked the Minister for Health the number of public dermatology centres providing topical immunotherapy (for example DPCP or SADBE) for extensive alopecia areata; the number treated in each of the past three years; the average waiting times; and whether capacity expansion is planned; and if she will make a statement on the matter. [30920/26]

1285. Deputy Cormac Devlin asked the Minister for Health to detail the availability of intralesional corticosteroid clinics for patchy alopecia areata, by hospital group; the average wait time from referral; and any actions to standardise access nationally; and if she will make a statement on the matter. [30921/26]

1286. Deputy Cormac Devlin asked the Minister for Health if the HSE will establish a national registry to capture outcomes for alopecia areata (for example, SALT 20 at week 24, durability, relapse), adverse events and service activity; the proposed data controller and governance; and the expected start date; and if she will make a statement on the matter. [30922/26]

1287. Deputy Cormac Devlin asked the Minister for Health if she will issue guidance on vaccination including the shingles vaccination and infection-risk mitigation for patients commencing JAK inhibitors for alopecia areata, including funding and delivery arrangements; and if she will make a statement on the matter. [30923/26]

1288. Deputy Brendan Smith asked the Minister for Health further to Parliamentary Question No. 1677 of 18 March 2026, the progress to date in finalising a strategy; when same will be published; and if she will make a statement on the matter. [30940/26]

1289. Deputy John McGuinness asked the Minister for Health further to Parliamentary Question No. 1990 of 18 March 2026, if she will request a comprehensive report from the HSE, TUSLA and the Gardaí relative to the current urgent care needs of the person, as the response to the PQ is inadequate and does not address the dire circumstances faced by the family on a daily basis; if she will provide a name and contact deta…

1290. Deputy Robert Troy asked the Minister for Health further to Parliamentary Question No. 2231 of 18 March 2026, given that the HSE has not provided a reply, when a response will issue in relation to the matter. [30946/26]

1291. Deputy Niamh Smyth asked the Minister for Health to review a case (details supplied); to provide an update on the place requested by the family; and if she will make a statement on the matter. [30959/26]

1292. Deputy Tony McCormack asked the Minister for Health whether she is aware that the taxation of near-neighbour community payments arising from onshore wind farm developments affects eligibility for the means tested medical card; and if she will make a statement on the matter. [31559/26]

1293. Deputy Roderic O'Gorman asked the Minister for Further and Higher Education, Research, Innovation and Science if he and his Department are aware of the work and early outcomes of the Advanced Research and Invention Agency in the United Kingdom; whether consideration has been given to establishing a similar high-risk, high-reward research funding body in Ireland; and if he will outline any plans to develop compa…